Clinical Breast Cancer

Published by: Elsevier Inc.  

People

  1. Hudis
    Hudis
  2. Seidman
    Seidman
  3. Norton
    Norton
  4. D'Andrea-Carlino
    D'Andrea-Carlino
  5. Fornier
    Fornier
  6. Modi
    Modi
  7. Dang
    Dang
  8. Lake
    Lake
  9. Traina
    Traina
  10. Sugarman
    Sugarman

Groups

  1. Department of Medicine (47)
  2. Solid Tumor Oncology Division (46)
  3. Breast Medicine Service (45)
  4. Survivorship Research (36)
  5. Alan and Sandra Gerry Metastasis and Tumor Ecosystems Center (12)
  6. Biostatistics Service (12)
  7. Epidemiology and Biostatistics (12)
  8. GSK Faculty (8)
  9. Radiology, Department of (8)
  10. Population Sciences Research Program (7)
Search Within
Formats
  1. Journal Article (59)
  2. Review (3)
Groups
  1. Department of Medicine (47)
  2. Solid Tumor Oncology Division (46)
  3. Breast Medicine Service (45)
  4. Survivorship Research (36)
  5. Alan and Sandra Gerry Metastasis and Tumor Ecosystems Center (12)
  6. Biostatistics Service (12)

More Groups

People
  1. Clifford Hudis (26)
  2. Andrew Seidman (19)
  3. Larry Norton (10)
  4. Sujata Patil (10)
  5. Gabriella D'Andrea-Carlino (8)
  6. Monica Fornier (8)

More People

Years
  1. 2022 (5)
  2. 2021 (2)
  3. 2020 (2)
  4. 2018 (5)
  5. 2017 (4)
  6. 2016 (4)

More Years

Publishers
  1. Elsevier Inc. (62)

Results (62)


Citation style sort is year ascending, and then by author or title. Author ascending is default.
  • Are we overtreating patients with T1(a) HER2+ breast cancer? An Analysis of the National Cancer Database
    Journal Article

    Williams, A. D.; Solis, O.; Sterbling, H. M.; Murray, A.; Sogunro, O.; De La Cruz, L. M.
    Clinical Breast Cancer (2022)

    Fulltext@MSK | Save
  • Olaparib use in patients with metastatic breast cancer harboring somatic BRCA1/2 mutations or mutations in non-BRCA1/2, DNA damage repair genes
    Journal Article

    Walsh, E. M.; Mangini, N.; Fetting, J.; Armstrong, D.; Chan, I. S.; Connolly, R. M.; Fiallos, K.; Lehman, J.; Nunes, R.; Petry, D.; more...
    Clinical Breast Cancer (2022)

    Fulltext@MSK | Save
  • Tumor immune microenvironment and response to neoadjuvant chemotherapy in hormone receptor/HER2+ early stage breast cancer
    Journal Article

    Vanguri, R. S.; Fenn, K. M.; Kearney, M. R.; Wang, Q.; Guo, H.; Marks, D. K.; Chin, C.; Alcus, C. F.; Thompson, J. B.; Leu, C. S.; more...
    Clinical Breast Cancer (2022)

    Fulltext@MSK | Save
  • The use of neoadjuvant therapy increases the rate of breast conservation in men with locally advanced breast cancer
    Journal Article

    Williams, A. D.; Ciocca, R.; Sabol, J. L.; Carp, N. Z.
    Clinical Breast Cancer (2022)

    Fulltext@MSK | Save
  • Genomic characterization of de novo metastatic breast cancer
    Review

    Mullangi, S.; Vasan, N.
    Clinical Breast Cancer (2022)

    Fulltext@MSK | Save
  • Prevalence, outcome, and management of risk factors in patients with breast cancer with peripheral arterial disease: A tertiary cancer center's experience
    Journal Article

    Bryce, Y.; Bourguillon, R.; Camacho Vazquez, J.; Ziv, E.; Kim, D.; Santos Martin, E.
    Clinical Breast Cancer (2021)

    Fulltext@MSK | Save
  • Breast-conserving surgery without radiation therapy for invasive cancer
    Review

    Montagna, G.; Morrow, M.
    Clinical Breast Cancer (2021)

    Fulltext@MSK | Save
  • Case-based review and clinical guidance on the use of genomic assays for early-stage breast cancer: Breast Cancer Therapy Expert Group (BCTEG)
    Review

    Kittaneh, M.; Badve, S.; Caldera, H.; Coleman, R.; Goetz, M. P.; Mahtani, R.; Mamounas, E.; Kalinsky, K.; Lower, E.; Pegram, M.; more...
    Clinical Breast Cancer (2020)

    Fulltext@MSK | Save
  • Incidence and management of diarrhea with adjuvant pertuzumab and trastuzumab in patients with human epidermal growth factor receptor 2-positive breast cancer
    Journal Article

    Bines, J.; Procter, M.; Restuccia, E.; Viale, G.; Zardavas, D.; Suter, T.; Arahmani, A.; Van Dooren, V.; Baselga, J.; Clark, E.; more...
    Clinical Breast Cancer (2020)

    Fulltext@MSK | Save
  • Phase 2 study of dose-dense doxorubicin and cyclophosphamide followed by eribulin mesylate with or without prophylactic growth factor for adjuvant treatment of early-stage human epidermal growth factor receptor 2–negative breast cancer
    Journal Article

    Cadoo, K. A.; Kaufman, P. A.; Seidman, A. D.; Chang, C.; Xing, D.; Traina, T. A.
    Clinical Breast Cancer (2018)

    Fulltext@MSK | Save

    • Clinical Breast Cancer – authorized name for:

    Name ISSN / ISBN Publisher
    Clinical Breast Cancer 15268209 Unknown
    Clinical Breast Cancer 15268209 Elsevier Inc.
    Clinical Breast Cancer 15268209 The Authors
    Clinical Breast Cancer 1526-8209 Elsevier Inc.
    Clinical Breast Cancer 15268209 2022
    Clinical Breast Cancer 1526-8209 Elsevier Inc.
    Clinical Breast Cancer 19380666 2011
    Clinical Breast Cancer 1526-8209 Cig Media Group, Lp
    Clinical Breast Cancer 1526-8209 Unknown
    Clinical breast cancer 19380666 Unknown